Clinical Trial Detail

NCT ID NCT02669173
Title Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Case Comprehensive Cancer Center
Indications

malignant glioma

Therapies

Bevacizumab + Capecitabine

Age Groups: adult

No variant requirements are available.